Compare · MIRM vs TVTX
MIRM vs TVTX
Side-by-side comparison of Mirum Pharmaceuticals Inc. (MIRM) and Travere Therapeutics Inc. (TVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MIRM and TVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MIRM is the larger of the two at $5.35B, about 1.1x TVTX ($4.98B).
- MIRM has been more active in the news (11 items in the past 4 weeks vs 5 for TVTX).
- Both have 25 recent analyst ratings on file.
- Company
- Mirum Pharmaceuticals Inc.
- Travere Therapeutics Inc.
- Price
- -
- -
- Market cap
- $5.35B
- $4.98B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 11
- 5
- Recent ratings
- 25
- 25
Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
Travere Therapeutics Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest MIRM
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Mirum Pharmaceuticals Inc.
- SEC Form 8-K filed by Mirum Pharmaceuticals Inc.
- Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
- SEC Form 4 filed by Mirum Pharmaceuticals Inc.
- Mirum Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
- Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
- Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Latest TVTX
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
- Travere Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Travere Therapeutics Announces Planned Chief Executive Officer Transition
- Chief Research Officer Rote William E. exercised 191,500 shares at a strike of $21.40 and sold $13,135,397 worth of shares (209,048 units at $62.83) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 98,197 units (SEC Form 4)
- EVP, CHIEF COMMERCIAL OFFICER Heerma Peter exercised 258,189 shares at a strike of $15.69 and sold $17,857,830 worth of shares (283,189 units at $63.06) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 117,066 units (SEC Form 4)
- EVP, Head of R&D & CMO Inrig Jula exercised 32,395 shares at a strike of $8.93 and sold $2,785,021 worth of shares (44,674 units at $62.34) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 100,491 units (SEC Form 4)
- Chief Legal Officer and GC Reed Elizabeth E exercised 37,500 shares at a strike of $15.46 and sold $2,337,695 worth of shares (37,500 units at $62.34) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Dube Eric M exercised 400,000 shares at a strike of $23.34 and sold $25,390,729 worth of shares (400,000 units at $63.48) as part of a pre-agreed trading plan (SEC Form 4)